Shares of Tesaro Inc. (NASDAQ:TSRO) have been assigned a consensus recommendation of “Buy” from the sixteen ratings firms that are currently covering the firm. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $119.12.
A number of equities research analysts have recently commented on the stock. RBC Capital Markets reaffirmed an “outperform” rating and set a $122.00 price objective on shares of Tesaro in a research note on Wednesday, August 24th. Leerink Swann reiterated an “outperform” rating and set a $108.00 target price on shares of Tesaro in a research report on Thursday, August 25th. Credit Suisse Group AG reiterated an “outperform” rating and set a $122.00 target price (up previously from $90.00) on shares of Tesaro in a research report on Monday, October 10th. Wedbush reiterated a “buy” rating on shares of Tesaro in a research report on Friday, August 5th. Finally, Zacks Investment Research lowered Tesaro from a “hold” rating to a “sell” rating in a research report on Tuesday, October 11th.
Tesaro (NASDAQ:TSRO) traded up 1.833% on Friday, reaching $140.255. 328,593 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $122.09 and a 200 day moving average price of $87.79. The firm’s market cap is $7.25 billion. Tesaro has a one year low of $29.51 and a one year high of $148.74.
Tesaro (NASDAQ:TSRO) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.98) EPS for the quarter, missing analysts’ consensus estimates of ($1.92) by $0.06. The firm had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.39 million. Tesaro had a negative return on equity of 141.88% and a negative net margin of 798.68%. Tesaro’s revenue for the quarter was up 4187.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.66) EPS. On average, equities analysts anticipate that Tesaro will post ($7.42) earnings per share for the current year.
In other news, VP Jeffrey H. Hanke sold 29,166 shares of Tesaro stock in a transaction on Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the transaction, the vice president now owns 29,166 shares in the company, valued at approximately $2,509,442.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Martin H. Jr. Huber sold 327 shares of the firm’s stock in a transaction dated Wednesday, November 2nd. The stock was sold at an average price of $121.29, for a total value of $39,661.83. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $223,416.18. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Tesaro by 112.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,415 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 749 shares during the last quarter. Citizens Financial Group Inc RI acquired a new stake in shares of Tesaro during the third quarter worth about $154,000. CenturyLink Investment Management Co acquired a new stake in shares of Tesaro during the third quarter worth about $172,000. Pacer Advisors Inc. acquired a new stake in shares of Tesaro during the third quarter worth about $216,000. Finally, KCG Holdings Inc. acquired a new stake in shares of Tesaro during the second quarter worth about $228,000. 90.42% of the stock is owned by hedge funds and other institutional investors.